Sartorius (OTCMKTS:SARTF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Saturday. The brokerage currently has a $128.00 price objective on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 16.36% from the company’s current price.
According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Shares of Sartorius (SARTF) opened at $110.00 on Friday. Sartorius has a 52 week low of $82.15 and a 52 week high of $114.64. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.92 and a quick ratio of 1.21.
TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/05/sartorius-sartf-rating-increased-to-buy-at-zacks-investment-research.html.
Sartorius Aktiengesellschaft provides laboratory and process technologies and equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.